By Adriano Marchese
Knight Therapeutics has agreed to acquire generics and specialty branded pharmaceutical company Paladin Pharma for 120 million Canadian dollars ($83.1 million).
The specialty pharmaceutical company said Tuesday it has entered into a definitive asset-purchase agreement with Endo Operations and Paladin Pharma for the acquisition. The upfront payment in cash will also include inventory with a value of C$20 million.
Knight said that it may also pay up to another US$15 million for reaching certain milestones.
Knight Chief Executive Samira Sakhia said the synergistic transaction adds critical mass and significantly increases the size of its Canadian business as well as in Latin America.
"The acquisition adds a portfolio of stable cash flow generating pharmaceuticals that will help fund our growth in Canada and Latin America," Sakhia said.
The transaction is expected to close sometime mid-year.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
March 11, 2025 08:25 ET (12:25 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。